WHITE PLAINS, N.Y., May 26, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society is committed to bringing
Chronic lymphocytic leukemia is the most common type of leukemia, with approximately 14,990 new cases diagnosed each year. In the last several years, new CLL therapies have been developed and FDA-approved, and outcomes for people living with CLL are steadily improving. During the program on June 21, Dr. O'Brien will discuss CLL treatment options, including new and emerging therapies currently being studied in clinical trials. This program, offered by The Leukemia & Lymphoma Society, is supported by educational grants from Cephalon Oncology and sanofi aventis and is presented in collaboration with Abrale and Alianza Latina. Continuing education credit is available for nurses and social workers.
To register for the June 21 program CLL Update-Emerging Therapies in Spanish, please visit www.LLS.org/leukemiaeducationsp.
To register for CLL Update-Emerging Therapies in Portuguese, please visit www.LLS.org/leukemiaeducationpg.
To register for CLL Update-Emerging Therapies in English, please visit www.LLS.org/programs.
For information on other LLS programs, please visit www.LLS.org/programs or contact an Information Specialist at (800) 955-4572.
SOURCE The Leukemia & Lymphoma Society
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All